SBIR/STTR Research Award
SBIR Topic 105, Phase I, Reagent Development for Small Cell Number ChIC-seq
Award amount
$150,000Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ALPHATHERA
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- NS86KWYJH4K3
- Solicitation number
- Not reported
- Topic code
- NHLBI
Research abstract
The project goal is to develop reagents that can be used for mapping genome wide epigenetic changes during normal development and disease process in rare primary and patient cellsBecause conjugating proteins could result in inactivation of the proteinsit will be important to achieve efficient conjugation between antibodies and MNase while reserving the activities of both
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Generation of antibody-drug conjugates by proximity-based sortase-mediated ligation
- TRIM21-mediated degradation of antibody-targeted cytosolic proteins
- TABA: Tools for the site-specific labeling and immobilization of antibodies for immunoassays
- Preparation of site specific antibody drug conjugates by proximity based sortase ligation
- Tools for site specific antibody immobilization for immunoassays
Research funding history
6 SBIR/STTR records share this UEI (2017–2021). Reported award amounts total $4,739,674. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services